Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina(Seagen (United States)), Brian E. Toki(Seagen (United States)), Michael Torgov(Seagen (United States)), Brian A. Mendelsohn(Seagen (United States)), Charles G. Cerveny(Seagen (United States)), Dana F. Chace(Seagen (United States)), Ron L DeBlanc(Seagen (United States)), R Patrick Gearing(Seagen (United States)), Tim D. Bovee(Seagen (United States)), Clay B. Siegall(Seagen (United States)), Joseph A. Francisco(Seagen (United States)), Alan F. Wahl(Seagen (United States)), Damon L. Meyer(Seagen (United States)), Peter D. Senter(Seagen (United States))
Cited by 1,181
Abstract
Related Papers
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
R K Jain|PubMed|1990|578